• 1
    Bowman JM, Chown B, Lewis M, Pollock JM. Rh-isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978;118: 623627.
  • 2
    Trolle B. Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. Acta Obstet Gynecol Scand 1989;68: 4547.
  • 3
    MacKenzie IZ, Bichler J, Mason GC, et al. Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 2004;117: 154161.
  • 4
    Tovey LA, Townley A, Stevenson BJ, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983;2(8344):244246.
  • 5
    Thornton JG, Page C, Foote G, Arthur GR, Tovey LA, Scott JS. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. Br Med J 1989;298(6689):16711673.
  • 6
    MacKenzie IZ, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine antenatal rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999;106: 492497.
  • 7
    National Institute for Clinical Excellence [NICE]. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. Technology Appraisal 41. London: National Institute for Clinical Excellence, 2002.
  • 8
    Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987;317: 1098.
  • 9
    Judd WJ, Jenkins WJ. Assay of anti-D using the Technicon Auto-analyser and the international standard anti-D typing serum. J Clin Path 1970;23: 801804.
  • 10
    Bichler J, Schondorfer G, Pabst G, Andresen I. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG 2003;110: 3945.
  • 11
    Woelfer B, Schuchter K, Janisiw M, Hafner E, Philipp K, Panzer S. Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. Transfusion 2004;44: 512517.
  • 12
    Eklund J, Hermann M, Kjellman H, Pohja P. Turnover rate of anti-D IgG injected during pregnancy. Br Med J 1982;284: 854855.
  • 13
    Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987;1: 101112.
  • 14
    Smith GN, Griffiths B, Mollison DP, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injections. Lancet 1972;i: 12081212.
  • 15
    World Health Organisation. Prevention of Rh sensitisation. Geneva: W.H.O. Technical Report Series 468, 1971: 29.
  • 16
    Medical Research Council. Controlled trial of various anti-D dosages in suppression of rhesus sensitisation following pregnancy. Report to the Medical Research Council by the working party on the use of anti-D immunoglobulin for the prevention of the isoimmunisation of Rh-negative women during pregnancy. Br Med J 1974;ii: 7580.
  • 17
    Witter FR, Shirey RS, Nicol SL, Ness PM. Postinjection kinetics of antepartum Rh immune globulin. Am J Obstet Gynecol 1990;163: 784786.
  • 18
    Mayne S, Parker JH, Harden TA, Dodds SD, Beale JA. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. Br Med J 1997;515: 1588.
  • 19
    Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med 1995;5: 1519.